Tatva Chintan Pharma Chem share price
NSE: TATVAChemicalsSpecialty Chemicals
Tatva Chintan Pharma Chem at a glance
Tatva Chintan Pharma Chem (NSE: TATVA) closed at ₹1,914.30 on 19 Oct 2026, down 1.58% on the day. With a market capitalisation of ₹4,478 Cr, it ranks 839th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Chemicals sector; its industry is Specialty Chemicals.
At its last close the stock traded at 106.2× trailing earnings, against a return on equity of 5.4% in FY26. Over the past year the share price has risen 77.2%. Its 52-week range is ₹1,044.10 (30 Mar 2026) to ₹2,008.70 (8 Oct 2026); the last close is 4.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹167 Cr (+43.0% year on year) and net profit ₹16 Cr (+140.3%), on a consolidated basis. Promoters held 72.02% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹4,478 CrRank 839 on NSE
- P/E (trailing)
- 106.2×
- Price to book
- 3.14×FY26
- EPS (TTM)
- ₹21.97to Q1 FY27
- ROE
- 5.4%FY26
- ROCE
- 7.6%FY26
- Debt to equity
- 0.15FY26
- Net profit margin
- 8.3%FY26
- Book value / share
- ₹334.20FY26
- 52-week high
- ₹2,008.708 Oct 2026
- 52-week low
- ₹1,044.1030 Mar 2026
- 1-year return
- +77.2%
- RSI (14-day)
- 58.1
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.58% | +1.5% | +12.3% | +11.7% | +77.2% |
Tatva Chintan Pharma Chem quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹83 Cr | ₹86 Cr | ₹108 Cr | ₹117 Cr | ₹124 Cr | ₹131 Cr | ₹134 Cr | ₹167 Cr |
| Revenue YoY | −13.6% | +2.0% | +9.8% | +10.8% | +47.9% | +52.9% | +24.4% | +43.0% |
| Net profit | −₹1 Cr | ₹0 Cr | ₹1 Cr | ₹7 Cr | ₹10 Cr | ₹15 Cr | ₹10 Cr | ₹16 Cr |
| Net profit YoY | −108.5% | −96.0% | −89.3% | +27.6% | — | +10,735.7% | +901.9% | +140.3% |
| Net margin | −0.8% | 0.2% | 1.0% | 5.7% | 8.0% | 11.6% | 7.7% | 9.6% |
| EPS | −₹0.29 | ₹0.06 | ₹0.44 | ₹2.84 | ₹4.24 | ₹6.49 | ₹4.41 | ₹6.83 |
Tatva Chintan Pharma Chem financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹291 Cr | ₹428 Cr | ₹403 Cr | ₹379 Cr | ₹366 Cr | — |
| Operating profit | ₹59 Cr | ₹103 Cr | ₹42 Cr | ₹42 Cr | ₹0 Cr | — |
| Net profit | ₹51 Cr | ₹96 Cr | ₹40 Cr | ₹29 Cr | ₹0 Cr | — |
| EPS (₹) | ₹25.57 | ₹44.65 | ₹18.26 | ₹12.82 | ₹0.14 | — |
| Cash from operations | ₹24 Cr | ₹20 Cr | ₹28 Cr | ₹98 Cr | ₹25 Cr | — |
| Total debt | ₹27 Cr | ₹13 Cr | ₹4 Cr | ₹1 Cr | ₹0 Cr | ₹5 Cr |
| Shareholders' equity | ₹166 Cr | ₹473 Cr | ₹515 Cr | ₹737 Cr | ₹739 Cr | ₹782 Cr |
Tatva Chintan Pharma Chem shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| Foreign institutions | 3.30% | 3.26% | 3.39% | 4.17% | 3.82% | 3.93% |
| Domestic institutions | 5.46% | 5.11% | 3.86% | 3.33% | 2.99% | 3.11% |
| Non-institutions | 19.22% | 19.60% | 20.73% | 20.48% | 21.17% | 20.94% |
Tatva Chintan Pharma Chem vs peers
The listed Chemicals companies nearest to Tatva Chintan Pharma Chem by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LXCHEMLaxmi Organic Industries | ₹170.90 | −4.53% | −16.1% | ₹4,738 Cr | 59.8 | — |
| FOSECOINDFoseco India | ₹6,185.00 | −1.36% | +13.2% | ₹4,662 Cr | 50.9 | — |
| TANFACINDTanfac Ind | — | — | — | ₹4,568 Cr | — | — |
| TATVATatva Chintan Pharma Chem | ₹1,914.30 | −1.58% | +77.2% | ₹4,478 Cr | 106.2 | — |
| YASHOYasho Industries | ₹3,519.70 | −2.77% | +114.0% | ₹4,242 Cr | 167.8 | — |
| GUJALKALIGujarat Alkalies and Chemicals | ₹570.10 | −3.04% | +4.1% | ₹4,187 Cr | — | — |
| VISHNUVishnu Chemicals | ₹614.90 | −4.41% | +25.6% | ₹4,139 Cr | 29.1 | — |
Ask anything about Tatva Chintan Pharma Chem
Pivot answers on the live chart with evidence you can check, and tests strategies against TATVA's own history. Try: “Why has TATVA moved over the last three months?” · “Backtest a 50-day moving-average crossover on TATVA over five years” · “Compare TATVA with LXCHEM on margins and valuation”
Frequently asked questions about Tatva Chintan Pharma Chem
What is the share price of Tatva Chintan Pharma Chem today?
Tatva Chintan Pharma Chem (NSE: TATVA) last closed at ₹1,914.30 on 19 Oct 2026. Its 52-week high is ₹2,008.70 and its 52-week low is ₹1,044.10.
What is the market cap of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem's market capitalisation is ₹4,478 Cr (₹4,478 Cr) at the 19 Oct 2026 close, ranking 839th among the NSE companies Pivot tracks.
What is the P/E ratio of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem trades at a trailing P/E of 106.2. The median P/E of the 4 closest Chemicals peers by market cap is 59.8.
What is the ROE and ROCE of Tatva Chintan Pharma Chem?
Return on equity was 5.4% in FY26 and return on capital employed was 7.6% in FY26 (consolidated figures).
Is Tatva Chintan Pharma Chem a debt-free company?
No. Tatva Chintan Pharma Chem's debt-to-equity ratio was 0.15 in FY26, with total debt of ₹5 Cr.
What were Tatva Chintan Pharma Chem's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Tatva Chintan Pharma Chem reported revenue of ₹167 Cr, +43.0% year on year, and net profit of ₹16 Cr, +140.3% year on year.
How has Tatva Chintan Pharma Chem stock performed over the last year?
Tatva Chintan Pharma Chem's share price has risen 77.2% over the past year, +11.7% over three months and +12.3% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Tatva Chintan Pharma Chem?
As of 30 Jun 2026: promoters 72.02%, foreign institutions 3.93%, domestic institutions 3.11%, non-institutions 20.94%.
Who are Tatva Chintan Pharma Chem's competitors?
The listed Chemicals companies closest to Tatva Chintan Pharma Chem by market cap are Laxmi Organic Industries, Foseco India, Tanfac Ind, Yasho Industries, Gujarat Alkalies and Chemicals and Vishnu Chemicals.
Is Tatva Chintan Pharma Chem a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Tatva Chintan Pharma Chem's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TATVA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Chemicals stocks · companies starting with T · all NSE stocks · this page as text